Vaccines 2022

Takeda (Japan) has reported the first approval of its dengue vaccine, QDENGA, outside of Japan, specifically in Indonesia. The vaccine is a tetravalent (targeting serotypes 1, 2, 3, and 4), live-attenuated vaccine. It is approved for use in individuals aged 6 to 45, regardless of prior dengue exposure, and does not require pre-vaccination serological testing. The vaccine is constructed using an attenuated dengue virus serotype 2 "backbone." The vaccination schedule consists of two doses administered at a three-month interval.